To meet the nucleic acid requirement for the testing platform, dedicated pathologists select viable and cellular tumor sections/smears to optimize the tumor-to-stroma ratio and to minimize the admixed inflammatory cells, blood, mucin, and necrotic tumor cells. This evidence concerns the gene MUC5AC and neoplasm.